N-n Or N=c(-n)-n Containing (e.g., Hydrazines, Hydrazones, Or Guanidines, Etc.) Patents (Class 514/565)
-
Patent number: 8927030Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: GrantFiled: March 26, 2010Date of Patent: January 6, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
-
Publication number: 20140378534Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.Type: ApplicationFiled: September 8, 2014Publication date: December 25, 2014Applicant: THE ROCKEFELLER UNIVERSITYInventors: Sohail F. Tavazoie, Jia M. Loo
-
Patent number: 8895614Abstract: A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.Type: GrantFiled: July 10, 2014Date of Patent: November 25, 2014Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Patent number: 8895617Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: GrantFiled: August 4, 2014Date of Patent: November 25, 2014Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Patent number: 8895615Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: GrantFiled: August 4, 2014Date of Patent: November 25, 2014Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Patent number: 8895065Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.Type: GrantFiled: May 29, 2012Date of Patent: November 25, 2014Assignee: Wockhardt Ltd.Inventors: Yatendra Kumar Gupta, Girish Kumar Jain, Munish Talwar, Manoj Mashalkar
-
Patent number: 8895616Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: GrantFiled: August 4, 2014Date of Patent: November 25, 2014Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Patent number: 8895618Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: GrantFiled: August 4, 2014Date of Patent: November 25, 2014Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20140343153Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20140343000Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.Type: ApplicationFiled: July 24, 2014Publication date: November 20, 2014Inventors: Alicia Regueiro-Ren, Zheng Liu, Jacob Swidorski, Ny Sin, Brian Lee Venables, Sing-Yuen Sit, Yan Chen, Jie Chen, Nicholas A. Meanwell
-
Publication number: 20140343152Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20140343154Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Patent number: 8889740Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: GrantFiled: August 4, 2014Date of Patent: November 18, 2014Assignee: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Patent number: 8883131Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).Type: GrantFiled: October 26, 2010Date of Patent: November 11, 2014Inventors: Robert Peter Taylor, Kartar Singh Lalvani, Ajit Lalvani
-
Publication number: 20140328910Abstract: An ingestion method of creatine composition, taking orally the creatine composition with beverage, characterized in that, the creatine composition is taken orally by preparing creatine composition aqueous solution with dissolving the creatine composition over one minute into water heating at 80-100° C. and by mixing the creatine composition aqueous solution with the beverage having ordinary or cool temperature.Type: ApplicationFiled: November 9, 2012Publication date: November 6, 2014Inventors: Hirohisa Nishizawa, Haruhiko Sueoka
-
Patent number: 8871810Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.Type: GrantFiled: December 23, 2009Date of Patent: October 28, 2014Assignee: Cumberland Pharmaceuticals Inc.Inventors: Leo Pavliv, Amy Dix Rock
-
Publication number: 20140314842Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Publication number: 20140309308Abstract: The present invention is directed to a depilatory composition which comprisesa depilatory compound having a thiol group; and at least 0.1 wt % of arginine based on the total weight of the composition.Type: ApplicationFiled: November 13, 2012Publication date: October 16, 2014Applicant: Reckitt & Colman (Overseas) LimitedInventor: Jane Evison
-
Publication number: 20140301998Abstract: Disclosed is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a concentration of from 0.1 to 25% by weight, based on the total weight of the formulation.Type: ApplicationFiled: June 2, 2014Publication date: October 9, 2014Applicant: BEIERSDORF AGInventors: Rainer KROPKE, Jens NIELSEN, Kathrin WOLTER
-
Publication number: 20140302141Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: ApplicationFiled: February 24, 2014Publication date: October 9, 2014Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: FERNANDO G. TONEGUZZO, GLENN A. MEYER, Marcelo A. RICCI, Marcelo A. COPPARI, ANA C. PASTINI, GUSTAVO A. FISCHBEIN
-
Publication number: 20140286922Abstract: A method of measuring the effect of an active agent or a stressor on the baseline metabolic indicators of one or more hair follicles, the method including (a) obtaining one or more hair follicles; (b) placing the one or more hair follicles in a vessel, wherein the one or more hair follicles are positioned under one or more sensors; (c) using the one or more sensors to measure the one or more hair follicles' baseline metabolic indicators for both glycolysis and oxidative phosphorylation; (d) exposing the one or more hair follicles to an active agent or a stressor; and (e) using the one or more sensors to measure the one or more hair follicles' respondent metabolic indicators for both glycolysis and oxidative phosphorylation.Type: ApplicationFiled: March 19, 2014Publication date: September 25, 2014Applicant: The Procter & Gamble CompanyInventors: Ben Charlton HULETTE, Thomas Larry DAWSON, JR.
-
Publication number: 20140288117Abstract: The subject invention provides materials and methods for treating neurodegenerative diseases. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat Parkinson's Disease and/or complications associated with Parkinson's Disease. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of Parkinson's Disease in an at-risk patient and/or treat or prevent the onset of Parkinson's Disease-associated symptoms.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventor: Bill Piu CHAN
-
Publication number: 20140249228Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.Type: ApplicationFiled: April 2, 2014Publication date: September 4, 2014Applicant: NEURODERM, LTD.Inventors: Oron Yacoby-Zeevi, Mara Nemas
-
Publication number: 20140249231Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Applicant: NEURODERM, LTD.Inventors: Oron Yacoby-Zeevi, Mara Nemas
-
Publication number: 20140249229Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.Type: ApplicationFiled: April 2, 2014Publication date: September 4, 2014Applicant: NEURODERM, LTD.Inventors: Oron Yacoby-Zeevi, Mara Nemas
-
Publication number: 20140249180Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.Type: ApplicationFiled: October 3, 2012Publication date: September 4, 2014Applicants: National Center for Geriatrics and Gerontology, THE DOSHISHAInventors: Akihiko Takashima, Yoshiyuki Soeda, Hiroyuki Nagata, Yasuo Ihara, Tomohiro Miyasaka, Hachiro Sugimoto
-
Publication number: 20140249230Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Applicant: NEURODERM, LTD.Inventors: Oron Yacoby-Zeevi, Mara Nemas
-
Patent number: 8815950Abstract: The present invention relates to stable dosage forms and compositions of levodopa and carbidopa for the treatment of patients suffering from Parkinson's disease. The dosage forms and compositions comprise both solid and liquid formulations and result in stable pharmaceutical products. Such dosage forms and compositions comprise a metal chelator and a levodopa concentration from about 1 mg/mL to about 30 mg/mL.Type: GrantFiled: March 17, 2005Date of Patent: August 26, 2014Assignee: Janssen Biotech, Inc.Inventors: Julius Remenar, Orn Almarsson, Anthony J. Meehan, Jr., Zhong Zhang
-
Publication number: 20140235720Abstract: Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.Type: ApplicationFiled: April 29, 2014Publication date: August 21, 2014Applicant: Cumberland Pharmaceuticals Inc.Inventors: Leo Pavliv, Amy Dix Rock
-
Publication number: 20140228296Abstract: The present invention relates to the discovery that an increased fraction of albumin is carbamylated in patients suffering from kidney disease (e.g., end-stage renal disease) and that the fraction of carbamylated albumin is also correlated with increased disease severity, particularly risk of mortality. The present invention also relates to the discovery that free amino acids can reduce carbamylation of albumin. Based on these discoveries the present invention provides diagnostic and prognostic methods for patients suffering from, or suspected of suffering from kidney disease. The invention also provides methods for treating kidney disease by administration of a compound or composition that reduced protein carbamylation, such as free amino acids or dipeptides.Type: ApplicationFiled: July 13, 2012Publication date: August 14, 2014Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Anders H. Berg, S. Ananth Karumanchi, Ravi I. Thadhani
-
Publication number: 20140221489Abstract: A method of eliminating or significantly decreasing shifts between dyskinesia and bradykinesia in a patient suffering from an advanced stage of Parkinson's Disease comprises for a predetermined time period intravenously, subcutaneously or intrathekally administering to the patient by continuous infusion a stable and therapeutically acceptable solution comprising at least 5 mg/ml of Levodopa.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: Dizlin Medical Design ABInventor: Nil Dizdar Segrell
-
Patent number: 8796337Abstract: A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.Type: GrantFiled: August 2, 2013Date of Patent: August 5, 2014Assignee: Adamas Pharmaceutical, Inc.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Patent number: 8791078Abstract: The invention relates to a dialysis solution for haemodialysis or peritoneal dialysis, said solution having a theoretical osmolarity within the range of from 250 to 550 mosm/L and a pH value within the range of from 4.9 to 8.0, said solution comprising a creatine compound and one or more electrolytes, wherein the concentration of the creatine compound is not more than 50 mM.Type: GrantFiled: July 21, 2010Date of Patent: July 29, 2014Assignee: Crearene Ltd.Inventor: Jan Bulle
-
Patent number: 8778997Abstract: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.Type: GrantFiled: May 9, 2011Date of Patent: July 15, 2014Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Yarlagadda Sudhakara Babu, Pooran Chand, Shanta Bantia, Shane Arnold, John Michael Kilpatrick
-
Patent number: 8748485Abstract: Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.Type: GrantFiled: December 1, 2011Date of Patent: June 10, 2014Assignee: Ono Pharmaceuticals Co., Ltd.Inventors: Masaya Kokubo, Koji Yano
-
Publication number: 20140154300Abstract: Methods and compositions for inducing apoptosis of cells, such as macrophages, at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas, nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system such as a catheter assembly, stent or other suitable device.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Florian Niklas Ludwig, Stephen Pacetti, Paul Consigny
-
Publication number: 20140142181Abstract: A method of topical application of a creatine composition for treating and/or inhibiting recurrence of muscle cramps/spasms as well as muscle pain and/or stiffness associated therewith.Type: ApplicationFiled: November 19, 2012Publication date: May 22, 2014Inventor: Stanley L. Mills
-
Publication number: 20140141069Abstract: The present invention relates to ?-guanidinopropionic acid for the prevention and/or treatment of hypertension associated with high baseline creatine kinase levels, not necessarily associated with hyperglycemia, impaired glucose tolerance, hyperinsulinemia, insulin insensitivity, hyperamilinemia, excess adiposity or hyperlipidemia, comprising administering to a subject in need thereof a therapeutically effective dosage of a pharmaceutical composition comprising ?-guanidinopropionic acid, or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 10, 2012Publication date: May 22, 2014Inventor: Lizzy Maritza Brewster
-
Patent number: 8729133Abstract: This invention relates to a process of treating/affecting cancers that are particularly susceptible to radiation therapy by administering to a host in need of such treatment an amino acid and radiation therapy.Type: GrantFiled: February 14, 2007Date of Patent: May 20, 2014Assignee: Cornell UniversityInventor: Leandro Carlos A Cerchietti
-
Publication number: 20140135396Abstract: The invention is directed to the treatment of patients at risk for liver damage due to the overingestion of acetaminophen by administering agents that increase hepatic levels of nitric oxide.Type: ApplicationFiled: July 4, 2012Publication date: May 15, 2014Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Wolfram Goessling, Andrew Cox, Trista North
-
Publication number: 20140135300Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Applicant: SUNOVION PHARMACEUTICALS INC.Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
-
Patent number: 8703816Abstract: Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.Type: GrantFiled: December 1, 2011Date of Patent: April 22, 2014Assignee: Ono Pharmaceuticals Co., Ltd.Inventors: Masaya Kokubo, Koji Yano
-
Patent number: 8703819Abstract: The use of guanidinoacetic acid and/or salts thereof in combination with choline and/or betaine to produce an agent for improving brain function, bone growth and the mineralization of bones, for improving cartilage growth, for alleviating aging processes, for strengthening the immune system, as an antioxidative and neuroprotective agent, for lowering the cholesterol and triglyceride value, for preventing inflammatory processes and for lowering the blood sugar level in humans and vertebrates is described. In this connection it has surprisingly turned out that the new agents have a considerably higher bioavailability and are thus better taken up into the cells than was previously known when using creatine.Type: GrantFiled: January 23, 2008Date of Patent: April 22, 2014Assignee: Alzchem Trostberg GmbHInventors: Thomas Gastner, Hans-Peter Krimmer
-
Patent number: 8703211Abstract: The invention relates to the treatment and prophylaxis of cancer. In particular, the invention relates to a pharmaceutical agent comprising strontium, amino acid(s) and mineral element(s), and its use in the preparation of an agent useful for the treatment and prophylaxis of cancer. The invention also relates to a method for treatment and prophylaxis of cancer.Type: GrantFiled: November 30, 2009Date of Patent: April 22, 2014Assignee: Oy Neurofood ABInventor: Thomas Tallberg
-
Publication number: 20140107207Abstract: The present invention provides a method for conveniently producing a protein formulation in which viruses are inactivated, without impairing the quality of the obtained protein formulation, characterized by including the step of exposing the protein formulation contaminated with the viruses to a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5. The present invention also provides a virus inactivation method characterized by including the step of contacting a virus-containing object with a 0.1-2M aqueous solution of arginine, an arginine derivative, or a mixture thereof, the aqueous solution being adjusted to pH 3.5 to 5.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: AJINOMOTO CO., INC.Inventors: Hajime Koyama, Tsutomu Arakawa, Daisuke Ejima
-
Publication number: 20140100284Abstract: The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly provide an arginine ingestion effect.Type: ApplicationFiled: December 12, 2013Publication date: April 10, 2014Applicants: National University Corporation Nagoya University, Kyowa Hakko Bio Co., Ltd.Inventors: Masayuki OCHIAI, Koji MORISHITA, Toshio HAYASHI
-
Publication number: 20140072618Abstract: A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as promoting hair growth on scalp tissuelacking sufficient hair, restoring normal sexual function in males with erectile dysfunction. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the scalp or penis. The preparation also contains an agent which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of choline chloride, magnesium chloride and sodium chloride.Type: ApplicationFiled: November 5, 2013Publication date: March 13, 2014Applicant: STRATEGIC SCIENCE & TECHNOLOGIES, LLCInventor: Eric T. Fossel
-
Publication number: 20140066511Abstract: A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as promoting hair growth on scalp tissue lacking sufficient hair, restoring normal sexual function in males with erectile dysfunction. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the scalp or penis. The preparation also contains an agent which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of choline chloride, magnesium chloride and sodium chloride.Type: ApplicationFiled: October 30, 2013Publication date: March 6, 2014Applicant: Strategic Science & Technologies, LLCInventor: Eric T. Fossel
-
Publication number: 20140066512Abstract: The present invention relates to rehydration and nutritional products comprising creatine and/or its salts, or analogues or precursors thereof, in ready to use aqueous oral compositions, such as gels, pastes and the like, and products for reconstitution in water, for use by humans and animals, together with processes for their preparation and uses thereof.Type: ApplicationFiled: May 1, 2012Publication date: March 6, 2014Applicant: PATENTNAV IRELAND LTDInventor: Edward O'Gorman
-
Publication number: 20140056862Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and ?-ketoglutarate. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.Type: ApplicationFiled: April 18, 2012Publication date: February 27, 2014Applicant: Nestec S.A.Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager